GILEAD SCIENCES, INC. v. NATCO PHARMA LIMITED
2:11-cv-04969
Overview
Parties
Defendant
NATCO PHARMA LIMITED NPE (University / Research)
Represented By
0 Attorneys ListedPlaintiff
F. HOFFMANN-LA ROCHE LTD. Operating Company
Represented By
0 Attorneys ListedCourt & Judges
Court
District Court, D. New Jersey (njd)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 2 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 5,763,483 A Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 930695 P | US Continuation / Sibling | View Official Patent → |
CG Technology Development, LLC v. FanDuel, Inc.
CG Technology Development, LLC v. DraftKings, Inc.
CG Technology Development, LLC v. bwin.party digital entertainment PLC
Gilead Sciences, Inc. v. Natco Pharma Limited
GILEAD SCIENCES, INC. v. NATCO PHARMA LIMITED
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US5763483
Carbocyclic compounds
|
Filed: 1996-12-27
Issued: 1998-06-09
|
Expired (Term Ended)
Expires: 2016-12-27
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
Standard Statutory Term β No obviousness-type double patenting truncation noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).